Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature-Reference-Cited by-同舟云学术

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature

Published:2014-12-05 Issue:6 Volume:23 Page:1827-1835
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Massey Paul R.,Okman Jonathan S.,Wilkerson Julia,Cowen Edward W.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-014-2520-9.pdf

Reference40 articles.

1. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312

2. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411–1416

3. Balagula Y, Rosen ST, Lacouture ME (2011) The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 65:624–635

4. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G (2005) Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 74:121–123

5. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma;Expert Opinion on Drug Metabolism & Toxicology;2024-09-03

2. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer;Expert Opinion on Pharmacotherapy;2024-08-12

3. A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy;Clinical Genitourinary Cancer;2024-06

4. Erworbene perforierende Dermatosen und Cabozantinib: eine neue kutane Toxizität;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-04

5. Acquired perforating dermatoses and cabozantinib: A novel cutaneous toxicity;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-03